Are you ready for the new asthma guideline?
New BTS/SIGN/NICE Guideline on Asthma: diagnosis, monitoring and chronic asthma management 2024
On the 28th November the joint National Institute for Health and Care Excellence (NICE), British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) will publish their long-awaited single guideline on asthma diagnosis, monitoring and management.
This update to the guideline is likely to represent a sea change in the management of asthma and will require significant change in primary care. Are you ready? This article provides links to relevant primary care-based tools to help you prepare. This list is not intended to be comprehensive but provides a starting point for helping you to prepare for and implement change in your practice in line with the new guidance.
You may also be interested in...
This is a high-level summary of what the new BTS/NICE/SIGN Asthma: diagnosis monitoring and chronic asthma management guideline means for you as a primary healthcare professional and what steps you need to take to implement it effectively.
Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers.
To consider how and when we use FeNO testing, we need to go to the definition of asthma. Both BTS/SIGN1 and GINA2 define it as a predominantly inflammatory disorder of the airways with airway hyperresponsiveness and variability in symptoms.